Dimorphic exanthema manifested as reticular maculopapular exanthema and erythema multiforme major associated with pyrazolon derivatives

European Journal of Dermatology

Volumn 12, Issue 5, 2002, Pages 488-490

  Chen, WenChieh ^a   Hsieh, Fu Sen ^a  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

Antipyrine; Dimorphic exanthema; Erythema multifome; NSAIDs; Reticular exanthem

Indexed keywords

ANTIBIOTIC AGENT; BLEOMYCIN; CEFALOTIN; CYPROHEPTADINE; DICLOFENAC; EPIRIZOLE; IBUPROFEN; METHYLPREDNISOLONE; NANDROLONE FURYLPROPIONATE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PENICILLAMINE; PHENAZONE; PIROXICAM; PYRAZOLONE DERIVATIVE; SALICYLIC ACID; SULINDAC; SULKERN; TENOXICAM;

AGED; ANTIBIOTIC PROPHYLAXIS; ARTICLE; BACTERIAL INFECTION; CASE REPORT; DIMORPHIC EXANTHEMA; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; ERYTHEMA MULTIFORME; FEVER; HEADACHE; HISTOPATHOLOGY; HUMAN; HYPERTENSION; MALE; PATCH TEST; RASH; RETICULAR MACULOPAPULAR EXANTHEMA; SKIN BIOPSY; SKIN MANIFESTATION; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS;

AGED; ANTI-BACTERIAL AGENTS; CYPROHEPTADINE; DRUG ERUPTIONS; DRUG THERAPY, COMBINATION; ERYTHEMA MULTIFORME; EXANTHEMA; FOLLOW-UP STUDIES; HUMANS; MALE; METHYLPREDNISOLONE; PATCH TESTS; PYRAZOLES; PYRAZOLONES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 0036750885     PISSN: 11671122     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Breathnack SM. Drug reactions. Textbook of dermatology. In: Champion RH, Burton JL, Ebling FJG, eds. 6th edn, Vol. 4. Oxford: Blackwell Scientific Publications, 1998: 3349-517.
2. Bork K. Cutaneous side effects of drugs. Philadelphia: WB Saunders, 1988: 37-9.
3. Hsiao CJ, Lee JY, Wong TW, Sheu HM. Extensive fixed drug eruption due to lamotrigine. Br J Dermatol 2001; 144: 1289-91.
4. Fritsch PO, Ruiz-Maldonado R. Erythema multiforme. In: Fitzpatrick's dermatology in general medicine. Freedberg IM, et al., eds. 5th edn, Vol. 1. New York: McGraw-Hill, 1999: 636-43.
5. Assier H, Bastuji-Garin S, Revuz J, Roujeau JC. Erythema multiforme with mucous membrane involvement and Stevens-Johnson syndrome are clinically different disorders with distinct causes. Arch Dermatol 1995; 131: 539-43.
6. Bigby M, Stern R. Cutaneous reactions to nonsteroidal anti-inflammatory drugs. A review. J Am Acad Dermatol 1985; 12: 866-76.
7. Roujeau JC, Kelly JP, Naldi L, Rzany B, Stern RS, Anderson T, Auquier A, Bastuji-Garin S, Correia O, Locati F. Medication use and the risk of Stevens-Johnson syndrome or toxic epiderma necrolysis. N Engl J Med 1995; 333: 1600-7.
8. Flower RJ, Moncada S, Vane JR. Analgesic-antipyretics and anti-inflammatory agents; drugs employed in the treatment of gout. In: Goodman Gilman et al. eds. Goodman and Gilman's The pharmacological basis of therapeutics, 7th ed, Macmillan, New York, 1985: 690-2.
9. Wright AL, Bleehen SS, Champion AE. Reticulate pigmentation due to bleomycin: light- and electron-microscopic studies. Dermatology 1990; 180: 255-7.
10. Aihara M, Kitamura K, Ikezawa Z. Lichenoid drug eruptions due to nandrolone furylpropionate (Demelon). J Dermatol 1989; 16: 330-4.
11. Alanko K. Topical provocation of fixed drug eruption. A study of 30 patients. Contact Dermatitis 1994; 31: 25-7.
12. Wolkenstein P, Chosidow O, Flechet ML, Robbiola O, Paul M, Dume L, Revuz J, Roujeau JC. Patch testing in severe cutaneous adverse drug reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis. Contact Dermatitis 1996; 35: 234-6.
13. Pichler WJ. Diagnostic possibilities in drug allergies. [German] Schweiz Med Wochenschr 1993; 123: 1183-92.
14. Bigby M. Nonsteroidal anti-inflammatory drug reactions. Semin Dermatol 1989; 8: 182-6.
15. Hernandez Fernandez de Rojas. Severe delayed adverse reactions to non-steroidal anti-inflammatory drugs (NSAIDs). Clin Exp Allergy 1998; 28 (suppl. 4): 47-51.